Shilpa Medicare Obtains Approval for Nor UDCA Tablets
Shilpa Medicare Limited, a prominent manufacturer of active pharmaceutical ingredients (APIs) and formulations, has achieved a significant milestone by receiving approval from the Subject Expert Committee (SEC) for its Investigational New Drug (IND) – Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg. This is a key step towards addressing non-alcoholic fatty liver disease (NAFLD), a crucial health concern affecting millions worldwide.
Understanding Non-Alcoholic Fatty Liver Disease
NAFLD has emerged as the most common liver disease, impacting nearly 25% of the global population, which translates to around 1.2 billion people. It is important to recognize that NAFLD can progress to non-alcoholic steatohepatitis (NASH), a serious condition that poses severe health risks. The approval of Nor UDCA is a response to the pressing need for effective treatments in this area.
Clinical Research and Results
Prior to the SEC approval, Shilpa Medicare successfully completed phase-3 clinical trials for Nor UDCA, designated as SMLNUD07. The trial was a phase III, randomized, double-blind, placebo-controlled, multicenter study aimed at investigating the safety and efficacy of Nor UDCA in patients diagnosed with NAFLD. The outcomes were promising, showcasing significant improvements across several critical measures.
Key Trial Findings
The clinical trial met all primary efficacy endpoints, yielding noteworthy results:
- Liver Fibrosis Reversal: An impressive 83.3% of participants demonstrated reversal of fibrosis, indicating a positive response to treatment.
- ALT Normalization: Recovery was also observed in elevated alanine transaminase (ALT) levels, a primary marker for NAFLD, with normalization occurring in approximately 90% of participants within just 12 weeks.
These findings underscore Nor UDCA's potential as a transformative therapy for NAFLD, with distinct advantages over existing treatments, including enhanced choleretic effects and anti-inflammatory properties.
Future Goals and Commitment
Mr. Vishnukant Bhutada, Managing Director at Shilpa Medicare, expressed enthusiasm over the SEC approval. He stated, "We are very pleased with this approval from SEC and hope to get the marketing authorization soon. Our team is dedicated to collaborating with regulatory bodies to ensure the timely introduction of this innovative treatment to patients. We anticipate launching it within the near future and aim to explore regulatory pathways in additional markets."
Company Vision and Services
Established in 1987, Shilpa Medicare has held a committed stance toward healthcare innovation. The company prides itself on delivering quality APIs, formulations, and biologics, supported by regulatory approvals from leading agencies worldwide. Additionally, Shilpa Medicare is recognized for offering comprehensive CDMO solutions tailored for a global clientele.
Frequently Asked Questions
What is Nor Ursodeoxycholic Acid (Nor UDCA)?
Nor UDCA is a novel treatment for non-alcoholic fatty liver disease aimed at reversing liver fibrosis and normalizing liver enzyme levels.
How does Shilpa Medicare intend to launch Nor UDCA?
The company plans to work closely with regulatory authorities to expedite marketing approval and hopes to launch the product in the near future.
What are the benefits of Nor UDCA compared to existing therapies?
Nor UDCA has shown enhanced efficacy in improving liver function and reducing inflammation, offering significant advantages over traditional treatments.
What is the significance of the SEC approval?
The SEC approval marks a critical step in bringing Nor UDCA to market, providing an essential new therapy for patients with NAFLD.
Can Nor UDCA be used worldwide?
Following the approval in certain markets, Shilpa Medicare intends to seek guidance from global regulatory authorities for international introduction of Nor UDCA.
